AuthorisedTherapeutic exploratory (Phase II)Interventional

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

This research study, called MEZI-KD, is investigating a new treatment approach for multiple myeloma, a type of blood cancer. It focuses on people whose myeloma has either returned after previous treatment or isn't responding to existing therapies. The study combines three medicines: mezigdomide (also known as CC-92480), carfilzomib, and dexamethasone. Researchers want to understand how effective this combination is at stopping the myeloma from growing and spreading. They will be looking at things like how long people live without their disease getting worse, how many people respond positively to the treatment, and the overall safety of this new combination. This is a Phase 2 study, meaning it’s a detailed look at the safety and effectiveness of the treatment in a specific patient group.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Assistance Publique Hopitaux De Paris

Enrolment target

Start

08 Apr 2026

Patients with relapsed/refractory symptomatic multiple myeloma (MM)

What is this study about?

This medical study is exploring a new treatment for a type of bone marrow cancer called multiple myeloma. This specific study is for people whose myeloma has either returned after they've had treatment before (this is called 'relapsed') or when the disease isn't getting better with current treatments (this is called 'refractory'). It's also suitable for people who are experiencing clear symptoms from their myeloma.

The study is testing a combination of three different medicines: mezigdomide, carfilzomib, and dexamethasone. Dexamethasone is mentioned a few times in the original notes, which simply means it's a key part of the treatment plan alongside the other two drugs. Doctors want to see if giving these three medicines together is a good way to manage and treat multiple myeloma in these situations.

The main goal of the study is to find out how long people live without their myeloma getting worse. This is an important way for doctors to measure if the treatment is working. They will also look at other key things, like how many people's cancer shrinks or goes away, how long these good responses last, and overall, how long people live after starting this treatment. Safety is a big part of any new treatment, so researchers will also be carefully monitoring for any side effects and how serious they are, to make sure the treatment is as safe as possible.

Key takeaways

This study is for adults with multiple myeloma that has come back or is not responding to treatment.
It examines a new combination of three medicines: mezigdomide, carfilzomib, and dexamethasone.
The main goal is to see how long people can live without their myeloma getting worse.
Researchers will also track other health changes, how the cancer responds, and safety.
It's a Phase 2 study, focusing on how well the treatment works and its safety in this patient group.

Who may be eligible?

To be considered for this study, you need to be an adult, aged 18 or older, and there's no upper age limit. Both men and women can participate.

The main requirement is that you have symptomatic multiple myeloma, and that your myeloma has either come back after previous treatments or isn't responding to the treatments you've had. This specific situation is often called 'relapsed or refractory multiple myeloma'.

There will be other detailed checks by the study doctors to make sure this is the right and safest study for you, depending on your overall health and medical history. This is to ensure everyone in the study is protected and the results are clear.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been diagnosed with multiple myeloma?
Has your multiple myeloma come back after treatment or isn't responding to previous treatments?
Are you currently experiencing symptoms from your multiple myeloma?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you will receive the three study medicines: mezigdomide, carfilzomib, and dexamethasone, according to a specific schedule decided by the study doctors. You will have regular appointments at the study centre, which will include blood tests, physical examinations, and other tests like scans to monitor your health and how your myeloma is responding to the treatment.

These visits will happen frequently at the start of the study and may become less common if your treatment is going well. The study team will track how long you respond to the treatment, how long you live without your disease getting worse, and your general health over time. The total duration of your participation could vary, as you would continue treatment as long as it is working for you and you are tolerating it well, followed by a period of monitoring.

Potential risks and benefits

Taking part in a clinical trial might offer benefits such as gaining access to a new treatment combination before it's widely available. Your health will be closely monitored, and you'll receive regular medical care from the study team. However, as with any new medicine, there are potential risks, including side effects from the drugs. Some side effects may be mild, while others could be more serious. The study team will explain all known and potential risks to you in detail. You are always in control and have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is multiple myeloma?

Multiple myeloma is a cancer of plasma cells, which are a type of white blood cell found in the bone marrow.

What does 'relapsed or refractory' mean?

This means your multiple myeloma has either come back after previous treatment, or it's not responding to the treatments you've already had.

What is a Phase 2 study?

A Phase 2 study is a stage of clinical research where doctors test a new treatment on a larger group of people to see if it's effective and to gather more information about its safety.

What are the medicines being tested?

The study is testing a combination of three medicines: mezigdomide, carfilzomib, and dexamethasone.

Will I get better if I join this study?

Participating in a study doesn't guarantee you'll get better, but it offers access to a new potential treatment. The study aims to find out how well it works and if it can help people with multiple myeloma.